UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2009
At a glance
- Drugs Pamidronic acid (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Aug 2009 New trial record